Jones D. Myopia management – the non-pharmaceutical options The 19th Hong Kong International Optometric Symposium, Virtual Keynote Address, November, 2021

Jones D. Myopia Management in Clinical Practice: Module 1: Why is myopia management essential in clinical practice Canadian Association of Optometrists – Online CE modules for Canadian ODs, March, 2021

Jones D. Myopia Management in Clinical Practice: Module 2: Myopia Management options Canadian Association of Optometrists – Online CE modules for Canadian ODs, March, 2021

Jones D. Myopia Management. Online module for Canadian Certified Optometric Assistants Canadian Association of Optometrists, Virtual presentation, April , 2021

Jones D. Myopia – How to control the Epidemic British Columbia Doctors of Optometry, Virtual Presentation, September 17, 2021

Jones D. Instrument Fundamentals - Workshop Global Myopia Symposium, Virtual Conference, September 19, 2021

Jones D. Multifunction Instruments Global Myopia Symposium, Virtual Conference, September 19, 2021

Jones D. Biometry in Myopia Management IACLE Global Webinar, September 22, 2021

Jones D, Thakrar V. Myopia Management in Clinical Practice: Module 3: How to implement myopia management in to clinical practice Canadian Association of Optometrists – Online CE modules for Canadian ODs, March, 2021

Jones DA, Luensmann D, Alton K, Werner L. The prevalence of refractive error in children in a Canadian rural, First Nation Community
American Academy of Optometry, Boston, 2021 [ PDF ]

Jones L. Contact lens comfort: Materials and methodologies to reduce drop outs Optician Contact Lens Week webinar, February 10, 2021

Jones L. Material and solution impacts on contact lens discomfort and dropout OVN (Netherlands Association of Optometrists) webinar, March 15, 2021

Jones L. Dry eye & contact lenses: COVID-19 did not help! Online Optom Learning Series, Webinar (India), March 6, 2021

Jones L. CLEAR report summary: Contact Lens Wettability, Cleaning, Disinfection and Interactions with Tears https://contactlensupdate.com/2021/06/15/contact-lens-wettability-cleaning-disinfection-and-interactions-with-tears/ 2021;60

Jones L. CLEAR: Future applications of contact lenses BCLA Virtual Clinical Conference & Exhibition, June 13, 2021

Jones L. Pandemic-Associated Eye Problems: A Review of Five Issues for the ECP https://contactlensupdate.com/2021/12/10/pandemic-associated-eye-problems-a-review-of-five-issues-for-the-ecp/ 2021;60

Jones L. What does the future for contacts look like? Nova Scotia Association of Optometrists meeting, webinar, Halifax Canada, November, 2021

Jones L. The contact lens practice of the future Nova Scotia Association of Optometrists meeting, webinar, Halifax Canada, November, 2021

Jones L. Myopia management update Nova Scotia Association of Optometrists meeting, webinar, Halifax Canada, November, 2021

Jones L. Potential future pharmaceutical options to manage dry eye disease Canadian Dry Eye Summit, Toronto, Canada, November, 2021

Jones L. Biomimicry & CL materials: Are we there yet? USA limited launch of Alcon Total30, online webinar, USA, December, 2021

Jones L, Stahl U, Guthrie S, Yang M, Moezzi A, Thom M. Contact Lens Compendium: Contact Lenses & Solutions Available in America. Vol 2 2021.

Jones L, Stahl U, Guthrie S, Yang M, Moezzi A, Thom M. Contact Lens Compendium: Contact Lenses and Solutions Available in Canada. Vol 47 2021.

Jones,L., Hui,A., Phan,C-M., Read,M. L., Azar,D., Buch,J., Ciolino,J. B., Naroo,S. A., Pall,B., Romond,K., Saknaridurg,P., Schnider,C. M., Terry,L., Willcox,M. CLEAR - Contact lens technologies of the future Contact Lens Anterior Eye 2021;44(2):398-430 [ Show Abstract ]

Contact lenses in the future will likely have functions other than correction of refractive error. Lenses designed to control the development of myopia are already commercially available. Contact lenses as drug delivery devices and powered through advancements in nanotechnology will open up further opportunities for unique uses of contact lenses.

This review examines the use, or potential use, of contact lenses aside from their role to correct refractive error. Contact lenses can be used to detect systemic and ocular surface diseases, treat and manage various ocular conditions and as devices that can correct presbyopia, control the development of myopia or be used for augmented vision. There is also discussion of new developments in contact lens packaging and storage cases.

The use of contact lenses as devices to detect systemic disease has mostly focussed on detecting changes to glucose levels in tears for monitoring diabetic control. Glucose can be detected using changes in colour, fluorescence or generation of electric signals by embedded sensors such as boronic acid, concanavalin A or glucose oxidase. Contact lenses that have gained regulatory approval can measure changes in intraocular pressure to monitor glaucoma by measuring small changes in corneal shape. Challenges include integrating sensors into contact lenses and detecting the signals generated. Various techniques are used to optimise uptake and release of the drugs to the ocular surface to treat diseases such as dry eye, glaucoma, infection and allergy. Contact lenses that either mechanically or electronically change their shape are being investigated for the management of presbyopia. Contact lenses that slow the development of myopia are based upon incorporating concentric rings of plus power, peripheral optical zone(s) with add power or non-monotonic variations in power. Various forms of these lenses have shown a reduction in myopia in clinical trials and are available in various markets.

Khanal,S., Ngo,W., Nichols,K. K., Wilson,L., Barnes,S., Nichols,J. J. Human meibum and tear film derived (O-acyl)-omega-hydroxy fatty acids in meibomian gland dysfunction Ocular Surface 2021;21(July):118-128 [ Show Abstract ]

Purpose: The molecular basis of the tear film and lipid layer alterations in meibomian gland dysfunction (MGD) is unknown. This study aimed to identify and compare (O-acyl)-omega-hydroxy fatty acids (OAHFAs) derived from human meibum and tears in MGD. Methods: Of 195 eligible subjects (18–84 years, 62.6% female), 183 and 174 provided samples for tears and meibum, respectively. Subjects were classified into four groups: Normal, Asymptomatic MGD, MGD, and Mixed. Samples from the right eye of each subject were infused into the SCIEX 5600 TripleTOF mass spectrometer in negative ion mode. Lipid intensities identified with Analyst1.7 TF and SCIEX LipidView1.3 were normalized by an internal standard and total ion current, then statistically compared in MetaboAnalyst 4.0. Results: In meibum and tears, 76 and 78 unique OAHFAs were identified, respectively. The five most frequent and abundant OAHFAs were 18:2/16:2, 18:1/32:1, 18:1/30:1, 18:2/32:1, and 18:1/34:1. Two OAHFAs, 18:2/20:2 and 18:2/20:1, were identified only in tears. Initial univariate analysis revealed three differently regulated OAHFAs in meibum and eight in tears. Partial Least Square Discriminant Analysis showed 18:1/32:1, 18:2/16:2, 18:1/34:1 and 18:0/32:1 in tears, and 18:2/16:2, 18:1/32:1 and 18:2/32:2 in meibum, had variable importance in projection scores >1.5 and contributed the most to the separation of groups. In both meibum and tears, all OAHFAS except 18:2/16:2 were reduced in MGD compared to the normal group. Conclusion: MGD is accompanied by differential expression of specific OAHFAs in meibum and tears. These results suggest OAHFAs play a role in the altered biochemical profile of the tear film lipid layer in humans with MGD.